Retraction Note: TRIB2 confers resistance to anti-cancer therapy by activating the serine/threonine protein kinase AKT

Affiliations

• ¹ Department of Biomedical Sciences and Medicine (DCBM), University of Algarve, Campus de Gambelas, Faro, 8005-139, Portugal.
• ² Centre for Biomedical Research (CBMR), University of Algarve, Campus de Gambelas, Faro, 8005-139, Portugal.
• ³ Brain Tumour Research Centre, Institute of Biomedical and Biomolecular Sciences, University of Portsmouth, PO1 2DT, Portsmouth, UK.
• ⁴ Bayer AG, Drug Discovery Oncology Research, Berlin, D-13342, Germany.
• ⁵ Genomics Unit, Centro Nacional de Investigaciones Cardiovasculares (CNIC), Madrid, 28029, Spain.
• ⁶ Department of Dermatology, University Hospital Essen, Essen, 45147, Germany.
• ⁷ Department of Cardiovascular Science, University of Sheffield, Sheffield, S10 2RX, UK.
• ⁸ Department of Molecular Biology and Genetics, Bilkent University, Ankara, 06533, Turkey.
• ⁹ Department of Biomedical Sciences and Medicine (DCBM), University of Algarve, Campus de Gambelas, Faro, 8005-139, Portugal. walink@ualg.pt.
• ¹⁰ Centre for Biomedical Research (CBMR), University of Algarve, Campus de Gambelas, Faro, 8005-139, Portugal. walink@ualg.pt.
• ¹¹ Algarve Biomedical Center (ABC), University of Algarve, Campus de Gambelas, Faro, 8005-139, Portugal. walink@ualg.pt.